References
- Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909–16.
- Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Prostate Cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56:584–91.
- Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.
- Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–83.
- Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009;101:1325–9.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–59.
- Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581–92.
- Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer – results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659–64.
- Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456–77.
- Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27–33.
- Wilson JMG, Junger G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968.
- van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1–8.
- van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int 2009;103:1472–7.
- Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med 2008;149:192–9.
- Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
- Hughes AM, Sladden MJ, Hirst GH, Ward JE. Community study of uncomplicated lower urinary tract symptoms among male Italian immigrants in Sydney, Australia. Eur Urol 2000;37:191–8.
- Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst 2009;101:1216–20.
- Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, Bratt O, Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol 2005;39:372–9.
- Abrahamsson PA, Artibani W, Chapple CR, Wirth M. European Association of Urology position statement on screening for prostate cancer. Eur Urol 2009;56:270–1.